Scarica l'app Stockscreener
18.08
5.42%
0.93
Pre-mercato:
18.07
-0.010
-0.06%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SMMT Giù?
Forum
Previsione
Summit Therapeutics Inc Borsa (SMMT) Ultime notizie
Summit Therapeutics (SMMT) Is Down 20.1% After Q1 2026 Net Loss Widens Sharply - simplywall.st
Summit Therapeutics falls after update on Akeso-partnered lung cancer trial - MSN
SMMT Technical Analysis | Trend, Signals & Chart Patterns | SUMMIT THERAPEUTICS INC (NASDAQ:SMMT) - ChartMill
How (SMMT) Movements Inform Risk Allocation Models - Stock Traders Daily
How to Summit up? Dis-Harmoni on ivonescimab NSCLC phase III - BioWorld News
SMMT Q1 Loss Narrower Than Expected, Stock Down on Ivonescimab Setback - Yahoo Finance
Summit Therapeutics: More Uncertainty Heading Into The ASCO Plenary (NASDAQ:SMMT) - Seeking Alpha
Investigation into Summit Therapeutics by Johnson Fistel - Intellectia AI
Summit Therapeutics Inc. Shareholders Are Encouraged to - GlobeNewswire
SMMT Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
H.C. Wainwright cuts Summit Therapeutics stock price target on trial risk - Investing.com Canada
H.C. Wainwright Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Cuts Target Price to $23 - Moomoo
We're Hopeful That Summit Therapeutics (NASDAQ:SMMT) Will Use Its Cash Wisely - Yahoo Finance
Summit Therapeutics Inc. (SMMT) Stock Analysis: Promising 91% Upside in the Biotech Sector - DirectorsTalk Interviews
Biopharmaceutical News: Summit Therapeutics Stock Plummets After Trial Analysis Misstep - geneonline.com
Analysts Offer Insights on Healthcare Companies: Adagene (ADAG) and Summit Therapeutics (SMMT) - The Globe and Mail
Summit Therapeutics Stock Plunges As Selling Pressure Intensifies - timothysykes.com
Roblox, Spotify, And Robinhood Are Among Top 10 Large-Cap Losers Last Week (April 27-May 1): Are The Others In Your Portfolio? - Benzinga
Summit Therapeutics Flags Significant Going-Concern Risk Amid Cash Shortfall and Uncertain Financing - The Globe and Mail
Summit Therapeutics (SMMT) Is Down 27.0% After HARMONi-6 OS Plenary, BLA Progress And Wider LossesHas The Bull Case Changed? - simplywall.st
This is why Summit Therapeutics (SMMT) is one of the Best Stocks to buy in a Rising Market - Yahoo Finance
TD Cowen Maintains Summit Therapeutics(SMMT.US) With Buy Rating - Moomoo
Summit Therapeutics (NASDAQ:SMMT) Issues Earnings Results - MarketBeat
SMMT Plunges As Summit Therapeutics Stock Sheds Over 27% - timothysykes.com
Summit Therapeutics (NASDAQ:SMMT) Raised to "Sell" at Wall Street Zen - MarketBeat
Summit Therapeutics Inc. Q1 2026 Financial Results: Forward-Looking Statements, Clinical Trial Updates, and Segment Reporting - Minichart
Summit Therapeutics Inc (SMMT) Stock Price, Quote, News & History - Benzinga
SMMT Stock Plunges On Wider Q1 Loss, Lung Cancer Clinical Trial Update - Stocktwits
Summit Therapeutics Shock Move Hits Nasdaq Futures - Kalkine Media
Merck's Biggest Looming Rival In Cancer Just Took A Gut Punch - Investor's Business Daily
U.S. Markets Closed Mixed Friday As Pershing Square Led, Summit Therapeutics Lagged - Barron's
Summit Therapeutics Shares Fall After 1Q Loss Widens - Moomoo
Summit Therapeutics Stock Plunges 23%: The Ivonescimab Update Shaking Its Keytruda Challenge - TechStock²
SMMT Maintains by Piper Sandler -- Price Target Lowered to $16.00 - GuruFocus
Summit Therapeutics (SMMT) Shares Drop 22% After Trial Update - GuruFocus
Summit Therapeutics (NASDAQ:SMMT) Shares Gap DownTime to Sell? - MarketBeat
Summit Therapeutics (SMMT) Sees Significant Drop in Stock Price - GuruFocus
Evercore Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $34 - Moomoo
Stifel Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $45 - Moomoo
Summit Therapeutics Stock Dips After Q1 Financial Report - Benzinga
Goldman Sachs Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $41 - Moomoo
Summit Therapeutics (SMMT) slides 24.7% as investors digest Q1 loss and an interim trial update that didn’t deliver an early efficacy win - Quiver Quantitative
Summit Therapeutics stock falls after Q1 update (SMMT:NASDAQ) - Seeking Alpha
Clear Street Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $31 - Moomoo
Summit’s ‘self-inflicted’ stumble; Esperion’s take-private deal - Yahoo Finance
Citi Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Summit Therapeutics price target lowered to $16 from $17 at Piper Sandler - TipRanks
Summit Therapeutics PLC $SMMT Shares Sold by Pictet Asset Management Holding SA - MarketBeat
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2026 - BioSpace
Clear Street Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Cuts Target Price to $31 - Moomoo
Impressive Progress for SMMT with New Bispecific Antibody Develo - GuruFocus
Summit Therapeutics (SMMT) Reports Q1 EPS Beat with Strong Cash Position - GuruFocus
SMMT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Summit Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Is Summit Therapeutics (SMMT) Attractive After Q1 2026? EPS $(0. - GuruFocus
11.97%
3.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):